Expression and clinical significance of the novel inhibitory cytokine IL-35 in patients with sepsis and multiple organ dysfunction syndrome

Objective To investigate the expression of interleukin-35 (IL-35) in patients with sepsis and multiple organ dysfunction syndrome (MODS), and to explore its effect on disease prognosis. Methods A prospective study was conducted. Twenty-two patients with sepsis and MODS were selected as study group, and 20 healthy volunteers were selected as controls. Blood samples of the patients and the volunteers were taken within 1 hour of the patient's visit, and cytokines, such as IL-35, IL-4, IL-10, IL-17, INF-γ, and TGF-β, were simultaneously detected by enzyme-linked immunosorbent assay (ELISA). The expression level of CD4+CD25+FOXP3+ Treg cells was detected by flow cytometry, and the acute physiology and chronic health status scoring systemⅡ (APACHE Ⅱ) was calculated. According to the survival outcome at 28 days after admission, the expression levels of IL-35 in the survival group (12 cases) and the death group (8 cases) were compared. The Spearman method was used to analyze the correlation between IL-35 level and the above indicators in patients with sepsis and MODS. Results Compared with the control group, the IL-35 levels were significantly increased in the study group (P 0.05). The IL-35 level in the death group was significantly lower than that in the survival group (P<0.05). IL-35 levels in the survival and death groups were analyzed by ROC curve with a AUC of 0.78 (P=0.03). The IL-35 level was negatively correlated with the APACHE-Ⅱ score in the study group (r=-0.78, P<0.01). Conclusions The IL-35 levels in patients with sepsis and MODS is significantly higher than that in healthy controls, and negatively correlated with APACHE Ⅱ score. The level of IL-35 has an important implication for the prognosis for patients with sepsis. Key words: Interleukin-35; Cytokine; Sepsis; Multiple Organ Dysfunction Syndrome; Immune